- Home
- NMT vs NTHI Comparison
NMT vs NTHI Comparison
Compare NMT & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMT | NTHI |
|---|---|---|
| Founded | 1993 | 2008 |
| Country | United States | United States |
| Employees | N/A | 5 |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.8M | 114.6M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | NMT | NTHI |
|---|---|---|
| Price | $12.78 | $4.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 16.2K | ★ 94.6K |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | ★ 3.21% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.11 | $3.71 |
| 52 Week High | $13.70 | $12.99 |
Technical Indicators
Market Signals| Indicator | NMT | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 51.76 | 40.59 |
| Support Level | $11.45 | $4.02 |
| Resistance Level | $13.18 | $5.78 |
| Average True Range (ATR) | 0.17 | 0.41 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 64.97 | 8.56 |
Price Performance
Historical ComparisonAbout NMT Nuveen Massachusetts Quality Municipal Income Fund
Nuveen Massachusetts Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's objective seeks to provide current income exempt from both regular federal and Massachusetts income taxes and to enhance portfolio value relative to the Massachusetts municipal bond market by investing in tax-exempt Massachusetts municipal obligations that are underrated or undervalued or that represent municipal market sectors that are undervalued.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.